DOCSLIB.ORG

Bioactive Molecules • Building Blocks • Intermediates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bioactive Molecules • Building Blocks • Intermediates • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Anti-Cancer Compound Library (96-well) Product Details: Catalog Number: CS-L025 Formulation: A collection of 4779 anti-cancer compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L025-1 1 2 3 4 5 6 7 8 9 10 11 12 SKF-96365 Fumarate MRT68921 a Empty (hydrochlorid ML162 ML-210 hydratase-IN- (dihydrochlori Peretinoin SR-3029 CBR-5884 Mivebresib AZD0156 Empty e) 1 de) HLCL-61 b Empty BAY-876 BAY1125976 BAY-1436032 Tomivosertib LY3177833 (hydrochlorid PQR620 AT-130 NSC 663284 MK-4101 Empty e) Flavopiridol c Empty Flavopiridol (Hydrochlorid SNS-032 Ko 143 KNK437 TA-02 Mitoquinone AZD-5438 R547 4-IBP Empty e) (mesylate) d Empty SAR-020106 HUHS015 SMER28 A-196 TPEN CP21R7 HC-067047 EAI045 RSL3 GSK6853 Empty IQ-1S (free Rho-Kinase- e Empty CZ415 SANT-1 ME0328 acid) GSK591 Madrasin SZL P1-41 IN-1 Nutlin-3a 9-amino-CPT Empty MELK-8a f Empty GNE-495 EPI-001 CA-074 BI-7273 BI-9564 CL-82198 MS049 Remetinostat (hydrochlorid MRK-016 Empty methyl ester e) SHP099 g Empty Nigericin BH3I-1 SHP099 (hydrochlorid (S)- NVP- F16 PF-04979064 Nevanimibe CFMTI Empty (sodium salt) e) ML753286 BAW2881 hydrochloride h Empty Ro 67-7476 GNF-6231 PHCCC FCCP Linaprazan UKI-1 BFH772 CPI-455 KDM5-IN-1 CAN508 Empty Plate layout: CS-L025-2 1 2 3 4 5 6 7 8 9 10 11 12 αvβ1 integrin- TM5275 a Empty CCF642 IMR-1 IMR-1A PACMA 31 PD-161570 HA15 WYE-132 IN-1 (TFA) (sodium) AEE788 Empty REV7/REV3L b Empty TCS-OX2-29 HO-3867 Plerixafor TPI-1 -IN-1 NSC781406 ZYZ-488 CPI-637 A-804598 TAK-243 Empty Rilmenidine c Empty Bay 59-3074 TBHQ (hemifumarat Rilmenidine Fisogatinib BP-1-102 SH5-07 GSK2256098 Tyrphostin M2698 Empty e) (phosphate) AG 528 GSK484 d Empty CID5721353 GLPG0187 Avadomide ITSA-1 NPS-1034 RAF709 (hydrochlorid NVS-PAK1-1 Aprepitant GKI-1 Empty e) e Empty FMK 9a ML385 LRE1 XMU-MP-1 PD150606 CD437 DTP3 DTP3 (TFA) Golgicide A INH6 Empty D-α- GSK-LSD1 Cyclo(RGDyK f Empty Hydroxyglutar FLLL32 (dihydrochlori GSK621 (S)-Crizotinib Tie2 kinase SecinH3 Tempol ) SGC2085 Empty ic acid de) inhibitor 1 (trifluoroaceta Cl-amidine g Empty Necrosulfona (hydrochlorid Acriflavine NH125 AGK2 Ferrostatin-1 (-)-(S)-Equol (±)-Equol Splitomicin SirReal2 Empty mide e) Sodium h Empty Nicaraven stibogluconat Urolithin A HJC0152 BMS453 CaCCinh-A01 AS1517499 BVT948 WNK463 APS-2-79 Empty e hydrochloride Plate layout: CS-L025-3 1 2 3 4 5 6 7 8 9 10 11 12 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com AZD5153 (6- Empty Ticagrelor Axitinib Hydroxy-2- Mycro 3 Y-33075 L002 JTE-013 CGS 15943 GSK2837808 MS-444 Empty a naphthoic A Y-33075 b Empty ML390 Propyl (dihydrochlori Lin28-let-7a SYP-5 TPOP146 NSC632839 Y-27632 Eganelisib GNE-272 Empty pyrazole triol de) antagonist 1 Histone c Empty GSK9311 Cambinol Acetyltransfer ML348 ML349 RA190 TPCA-1 S63845 GNE-140 (R)-GNE-140 Empty ase Inhibitor II (racemate) d Empty (S)-GNE-140 STF-62247 PSB-12379 CXD101 STAT3-IN-1 FUBP1-IN-1 Toxoflavin HTHQ CHS-828 Ciliobrevin A Empty NSC23005 Teglarinad e Empty (sodium) URB602 (chloride) Futibatinib 3-AP BGP-15 NCB-0846 UNC3866 GS-444217 JQEZ5 Empty TAK-659 f Empty IWP-O1 BRCA1-IN-2 (hydrochlorid Navitoclax WT-161 KRIBB11 Bisantrene GGTI298 GCN2-IN-1 Zibotentan Empty e) W-7 g Empty Acelarin BAY1082439 Simurosertib MX69 SAR-20347 OGT 2115 ML364 (hydrochlorid ML-9 MY-5445 Empty e) ATM-3507 h Empty CCCP CEP-40783 (trihydrochlori Beaucage (E)-AG 99 HA-100 10074-G5 Nrf2-IN-1 CCT251236 GSK 4027 Empty de) reagent Plate layout: CS-L025-4 1 2 3 4 5 6 7 8 9 10 11 12 ZK756326 a Empty GSK4028 ZINC1346675 LOM612 Sarcosine (dihydrochlori AG-494 D-erythro- Src Inhibitor 1 Kinetin TOFA Empty 1 de) Sphingosine riboside Acetylcholine b Empty Monastrol Salermide LY294002 NSC 228155 SKL2001 (iodide) CeMMEC13 RHPS4 AS-605240 KYA1797K Empty (2- Empty Importazole PD-1-IN-17 IC-87114 Hydroxypropy AR7 TG100-115 PF-06840003 EED226 666-15 TP-3654 Empty c l)-β- PI-103 Naltrindole d Empty PNU-74654 TGX-221 PGMI-004A SF2523 PI-103 (Hydrochlorid 2- (hydrochlorid Tesmilifene Ecteinascidin Empty e) Iodomelatonin e) (fumarate) 770 Tin- e Empty protoporphyri Silodosin Agmatine XMD16-5 ZINC0088152 RPI-1 L-732138 ODQ YKL-5-124 YKL-5-124 Empty n IX (sulfate) 4 (TFA) Milademetan f Empty Barasertib- (tosylate CHMFL-BMX- Barasertib STK16-IN-1 GDC-0326 EMT inhibitor- Thiomyristoyl ZM-447439 DMU2105 Empty HQPA hydrate) 078 1 Veliparib 3- g Empty DMU2139 Veliparib Iberdomide Pan-RAS-IN- PD-166866 (dihydrochlori R-IMPP Hesperin Harmane (Methylthio)pr Empty 1 de) opionic acid N-(5- SI-2 h Empty Aminopentyl) L-DABA RG14620 RG13022 Trolox (R)-Trolox (hydrochlorid PF-6274484 PBIT Ceefourin 1 Empty acetamide e) Plate layout: CS-L025-5 1 2 3 4 5 6 7 8 9 10 11 12 IT1t Trilaciclib a Empty SR0987 (dihydrochlori RAD51 (hydrochlorid (±)- Zanubrutinib Dihydromund LF3 GZD856 LY3214996 Empty de) Inhibitor B02 e) Zanubrutinib uletone (formic) MT-DADMe- Polyoxyethyle b Empty ImmA Pico145 F1063-0967 A-395 eIF4A3-IN-1 Cdc7-IN-1 TC13172 ne stearate AZD-5991 MRX-2843 Empty Elimusertib c Empty HI-TOPK-032 Linrodostat Avapritinib GDC-0077 GSK3326595 JNJ- Elimusertib (hydrochlorid BMS-986158 Roblitinib Empty 64619178 e) Nilotinib Empty Darovasertib Bosutinib Nilotinib NVX-207 (monohydroc Tozasertib MSC2530818 Olaparib Recilisib Ilaprazole Empty d hloride UAMC00039 e Empty LTURM34 Oxyphenisati IMD-0354 TM5441 PRN1371 (dihydrochlori BTB-1 CSF1R-IN-1 ML311 PHA-680632 Empty n acetate de) ZM223 Dasatinib f Empty EDO-S101 eIF4A3-IN-2 Danusertib (hydrochlorid NCGC002445 MLN8054 SK1-IN-1 Dasatinib (hydrochlorid CHIR-99021 Empty e) 36 e) CHIR-99021 CHIR-99021 EIPA g Empty (monohydroc (trihydrochlori DKM 2-93 dBET1 EIPA (hydrochlorid ML-18 FITM AX-15836 Fasentin Empty hloride) de) e) N6-(2- LYN-1604 h Empty STAT5-IN-1 Phenylethyl)a TG 100801 AU1235 Linsitinib Heparan NVP-TAE 684 Autophinib (dihydrochlori CM-272 Empty denosine Sulfate de) Plate layout: CS-L025-6 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com 1 2 3 4 5 6 7 8 9 10 11 12 Sepantronium a Empty KDM4D-IN-1 CU-CPT17e AZD-1480 hVEGF-IN-1 TNP-470 (bromide) BTK IN-1 LY 345899 SMI-16a AD80 Empty CB-1158 IACS-9571 b Empty SPI-112 NCT-503 Wortmannin AZ PFKFB3 Selitrectinib CPI-444 (dihydrochlori AZD4635 BMS-754807 (hydrochlorid Empty 26 de) e) Tandutinib c Empty Rucaparib Sorafenib BMS-1166 6-Biopterin Sorafenib Tandutinib A2A receptor FX1 KY1220 (hydrochlorid Empty (Camsylate) (Tosylate) antagonist 1 e) KDOAM-25 d Empty Linperlisib Oxamflatin CDK9-IN-8 OSI-930 (citrate) STAT5-IN-2 Cediranib WM-1119 MOZ-IN-2 Amuvatinib Empty Retaspimycin e Empty WM-8014 Dovitinib Pazopanib SAFit2 2OH-BNPP1 JPM-OEt Masitinib Masitinib (Hydrochlorid Tanespimycin Empty (lactate) (mesylate) e) f Empty BIIB021 Luminespib Everolimus Rapamycin Vorinostat Ixabepilone CUDC-101 Panobinostat Belinostat Bortezomib Empty Motesanib BRAF AKT Kinase NVP- g Empty Motesanib (Diphosphate) Midostaurin Saracatinib inhibitor RAF265 GSK-690693 Inhibitor ADW742 AG1024 Empty SB 203580 h Empty PD0325901 Sunitinib SB 203580 (hydrochlorid BAY 11-7085 Vandetanib Afatinib Afatinib BMS-536924 SB 202190 Empty e) (dimaleate) Plate layout: CS-L025-7 1 2 3 4 5 6 7 8 9 10 11 12 (+)-BAY- (±)-BAY- (-)-BAY- a Empty Omipalisib GSK-923295 HSF1A HMN-154 Gusacitinib 1251152 1251152 1251152 BAY-1816032 LY3200882 Empty BET EHNA b Empty Repotrectinib PIK-294 bromodomain Diethyl- T-3775440 E7046 R162 PU02 inS3-54A18 (hydrochlorid Empty inhibitor pythiDC hydrochloride e) 5'-N- Empty Ethylcarboxa Proxalutamid Doramapimod PD173074 Falnidamol D4476 Ro 90-7501 TCPOBOP Toyocamycin CL-387785 Empty c midoadenosin e Regorafenib d Empty TC ASK 10 GW788388 BAI1 PD176252 JNJ-7706621 Toceranib Toceranib Regorafenib Calmidazoliu (monohydrate Empty (phosphate) m chloride ) 1- e Empty BMS-690514 PETCM CA-074 Proglumide Brivanib Brivanib Foretinib Aminobenzotr KW-2449 Methylmaloni Empty (sodium) (alaninate) iazole c acid Tirbanibulin Fasudil f Empty Tirbanibulin (dihydrochlori Tirbanibulin (Hydrochlorid Enzastaurin Sotrastaurin AZD 6482 ARP-100 G15 PHTPP Empty de) (Mesylate) e) 5'- MK-2206 g Empty AV-412 Fluoroindirubi AV-412 (free JNJ0966 PI-273 Takinib AKT inhibitor (dihydrochlori DUPA(OtBu)- LCL521 Empty noxime base) VIII de) OH LCL521 4,4'- PROTAC PROTAC Amifostine (2R)-Octyl-α- (2S)-Octyl-α- h Empty dihydrochlorid Dimethoxybe PKM2-IN-1 CDK9 BET thiol hydroxyglutar hydroxyglutar GW779439X K00546 Empty e nzil Degrader-1 Degrader-1 (dihydrochlori ate ate Plate layout: CS-L025-8 1 2 3 4 5 6 7 8 9 10 11 12 Fmoc-1,6- IPN60090 Canertinib a Empty Tetraphenylp BI-78D3 MAK683 diaminohexan STING 2-HBA Canertinib IPN60090 (dihydrochlori (dihydrochlori Empty orphyrin e agonist-3 de) de) Samuraciclib b Empty PF-06726304 NAZ2329 CD73-IN-1 PTC-028 Gardiquimod iCRT3 ROC-325 Pim1/AKK1- IBR2 (hydrochlorid Empty (diTFA) IN-1 e) Samuraciclib c Empty (trihydrochlori Seclidemstat Ensartinib PP121 Semaxinib PD173955 Emricasan CTS-1027 BAY-320 BAY-524 Empty de) hydrochloride Fmoc-Ser(O- Empty α-D- Asciminib NecroX-5 Losmapimod L-Kynurenine PH-797804 IDH-305 Cintirorgon MKC8866 Vorasidenib Empty d GalNAc(OAc) Naphthol AS- e Empty Pamiparib QC6352 Lanifibranor
Load more

Recommended publications
  • 615 Neuroscience-Cayman-Bertin
    Thomas G. Brock, Ph.D. Introduction to Neuroscience In our first Biology classes, we learned that lipids form the membranes around cells. For many students, interests quickly moved to the intracellular constituents ‘that really matter’, or to how cells or systems work in health and disease. If there was further thought about lipids, it might have been limited to more personal issues, like an expanding waistline. It was easy to forget about lipids in the complexities of, say, Alzheimer’s Disease, where tau protein is hyperphosphorylated by a host of kinases before forming neurofibrillary tangles and amyloid precursor protein is processed by assorted secretases, ultimately aggregating to form neurodegenerating plaques. What possible role could lipids have in all this? After all, lipids just form the membranes around cells. Fortunately, neuroscientists study complex systems. Whether working at the molecular, cellular, or organismal level, the research focus always returns to the intricately interconnected bigger picture. Perhaps surprisingly, lipids keep emerging as part of the bigger picture. At least, the smaller lipids do. Many of the smaller lipids, including the cannabinoids and eicosanoids, act as paracrine hormones, modulating cell functions in a receptor-mediated fashion. In this sense, they are rather like the peptide hormones in their diversity and actions. In the neurosystem, this means that these signaling lipids determine if synapses fire or not, when cells differentiate or die, and whether tissues remain healthy or become inflamed. Returning to the question posed above about lipids in Alzheimer’s, these mediators have roles at many levels in the course of the disease, as presented in an article on page 42 of this catalog.
    [Show full text]
  • In Vitro Testicular Toxicity Models : Opportunities for Advancement Via Biomedical Engineering Techniques
    Erschienen in: Alternatives to Animal Experimentation : ALTEX ; 30 (2013), 3. - S. 353-377 http://dx.doi.org/10.14573/altex.2013.3.353 t4 Report* In Vitro Testicular Toxicity Models: Opportunities for Advancement via Biomedical Engineering Techniques Louise Parks Saldutti 1, Bruce K. Beyer 2, William Breslin 3, Terry R. Brown 4, Robert E. Chapin 5, Sarah Campion 5, Brian Enright 6, Elaine Faustman 7, Paul M. D. Foster 8, Thomas Hartung 9, William Kelce 10, James H. Kim 11, Elizabeth G. Loboa 12, Aldert H. Piersma 13, David Seyler 14, Katie J. Turner 15, Hanry Yu 16, Xiaozhong Yu 17, and Jennifer C. Sasaki 18 1 2 Department of Development & Reproduction, Merck & Co., West Point, PA, USA; Department of Disposition, Safety 3 and Animal Research – Preclinical Safety, Sanofi U.S. Inc., Bridgewater, NJ, USA; Eli Lilly and Company, Lilly Research 4 Laboratories, Indianapolis, IN, USA; Department of Biochemistry & Molecular Biology, Johns Hopkins Bloomberg School of 5 Public Health, Baltimore, MD, USA; Pfizer Inc., Global R&D, Developmental and Reproductive Toxicology Group, Groton, 7 CT, USA; 6AbbVie Inc., North Chicago, IL, USA; University of Washington, Department of Environmental and Occupational 8 Health Sciences, Institute for Risk Analysis and Risk Communication, Seattle, WA, USA; National Toxicology Program, National Institutes of Environmental Health Sciences, National Institute of Health, Department of Health and Human Services, 9 Research Triangle Park, NC, USA; Johns Hopkins University, Bloomberg School of Public Health, Center for
    [Show full text]
  • Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer
    cancers Review Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer Viktoriia Cherkasova, Olga Kovalchuk * and Igor Kovalchuk * Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 7X8, Canada; [email protected] * Correspondence: [email protected] (O.K.); [email protected] (I.K.) Simple Summary: In recent years, multiple preclinical studies have shown that changes in endo- cannabinoid system signaling may have various effects on intestinal inflammation and colorectal cancer. However, not all tumors can respond to cannabinoid therapy in the same manner. Given that colorectal cancer is a heterogeneous disease with different genomic landscapes, experiments with cannabinoids should involve different molecular subtypes, emerging mutations, and various stages of the disease. We hope that this review can help researchers form a comprehensive understanding of cannabinoid interactions in colorectal cancer and intestinal bowel diseases. We believe that selecting a particular experimental model based on the disease’s genetic landscape is a crucial step in the drug discovery, which eventually may tremendously benefit patient’s treatment outcomes and bring us one step closer to individualized medicine. Abstract: Despite the multiple preventive measures and treatment options, colorectal cancer holds a significant place in the world’s disease and mortality rates. The development of novel therapy is in Citation: Cherkasova, V.; Kovalchuk, critical need, and based on recent experimental data, cannabinoids could become excellent candidates. O.; Kovalchuk, I. Cannabinoids and This review covered known experimental studies regarding the effects of cannabinoids on intestinal Endocannabinoid System Changes in inflammation and colorectal cancer. In our opinion, because colorectal cancer is a heterogeneous Intestinal Inflammation and disease with different genomic landscapes, the choice of cannabinoids for tumor prevention and Colorectal Cancer.
    [Show full text]
  • National Center for Toxicological Research
    National Center for Toxicological Research Annual Report Research Accomplishments and Plans FY 2015 – FY 2016 Page 0 of 193 Table of Contents Preface – William Slikker, Jr., Ph.D. ................................................................................... 3 NCTR Vision ......................................................................................................................... 7 NCTR Mission ...................................................................................................................... 7 NCTR Strategic Plan ............................................................................................................ 7 NCTR Organizational Structure .......................................................................................... 8 NCTR Location and Facilities .............................................................................................. 9 NCTR Advances Research Through Outreach and Collaboration ................................... 10 NCTR Global Outreach and Training Activities ............................................................... 12 Global Summit on Regulatory Science .................................................................................................12 Training Activities .................................................................................................................................14 NCTR Scientists – Leaders in the Research Community .................................................. 15 Science Advisory Board ...................................................................................................
    [Show full text]
  • 2-Arachidonoylglycerol a Signaling Lipid with Manifold Actions in the Brain
    Progress in Lipid Research 71 (2018) 1–17 Contents lists available at ScienceDirect Progress in Lipid Research journal homepage: www.elsevier.com/locate/plipres Review 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain T ⁎ Marc P. Baggelaara,1, Mauro Maccarroneb,c,2, Mario van der Stelta, ,2 a Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands. b Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy c European Centre for Brain Research/IRCCS Santa Lucia Foundation, via del Fosso del Fiorano 65, 00143 Rome, Italy ABSTRACT 2-Arachidonoylglycerol (2-AG) is a signaling lipid in the central nervous system that is a key regulator of neurotransmitter release. 2-AG is an endocannabinoid that activates the cannabinoid CB1 receptor. It is involved in a wide array of (patho)physiological functions, such as emotion, cognition, energy balance, pain sensation and neuroinflammation. In this review, we describe the biosynthetic and metabolic pathways of 2-AG and how chemical and genetic perturbation of these pathways has led to insight in the biological role of this signaling lipid. Finally, we discuss the potential therapeutic benefits of modulating 2-AG levels in the brain. 1. Introduction [24–26], locomotor activity [27,28], learning and memory [29,30], epileptogenesis [31], neuroprotection [32], pain sensation [33], mood 2-Arachidonoylglycerol (2-AG) is one of the most extensively stu- [34,35], stress and anxiety [36], addiction [37], and reward [38]. CB1 died monoacylglycerols. It acts as an important signal and as an in- receptor signaling is tightly regulated by biosynthetic and catabolic termediate in lipid metabolism [1,2].
    [Show full text]
  • TAAR1 Activation Modulates Monoaminergic Neurotransmission, Preventing Hyperdopaminergic and Hypoglutamatergic Activity
    TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity Florent G. Revela, Jean-Luc Moreaua, Raul R. Gainetdinovb, Amyaouch Bradaiac, Tatyana D. Sotnikovab, Roland Morya, Sean Durkina, Katrin Groebke Zbindend, Roger Norcrossd, Claas A. Meyere, Veit Metzlera, Sylvie Chaboza, Laurence Ozmena, Gerhard Trubea, Bruno Pouzeta, Bernhard Bettlerf, Marc G. Carong, Joseph G. Wettsteina, and Marius C. Hoenera,1 aNeuroscience Research, dDiscovery Chemistry, and eDiscovery Technologies, Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland; bDepartment of Neuroscience and Brain Technologies, Italian Institute of Technology, 16163 Genoa, Italy; cNeuroservice, Domaine de Saint-Hilaire, 13593 Aix-en-Provence, France; fDepartment of Biomedicine, Institute of Physiology, Pharmazentrum, University of Basel, CH-4056 Basel, Switzerland; and gDepartment of Cell Biology, Duke University Medical Center, Durham, NC 27710 Edited by Richard D. Palmiter, University of Washington, Seattle, WA, and approved March 31, 2011 (received for review February 24, 2011) The trace amine-associated receptor 1 (TAAR1), activated by en- sitive to the locomotor-stimulating effect of d-amphetamine dogenous metabolites of amino acids like the trace amines and show elevated striatal release of dopamine (DA), noradren- p-tyramine and β-phenylethylamine, has proven to be an impor- aline (NA), and serotonin [5-hydroxytryptamine (5-HT)] after a d-amphetamine challenge (10, 12). Furthermore, the spontaneous tant modulator of the dopaminergic system and is considered −/− firing rate of the VTA DA neurons is augmented in Taar1 mice, a promising target for the treatment of neuropsychiatric disorders. fi To decipher the brain functions of TAAR1, a selective TAAR1 ago- and only in WT mice does pTyr decrease this ring rate (10).
    [Show full text]
  • 'Gating' Residues Ile199 and Tyr326 in Human Monoamine Oxidase B
    The ‘gating’ residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition Erika M. Milczek1,*, Claudia Binda2, Stefano Rovida2, Andrea Mattevi2 and Dale E. Edmondson1 1 Departments of Chemistry and Biochemistry, Emory University, Atlanta, Georgia, USA 2 Department of Genetics and Microbiology, University of Pavia, Italy Keywords The major structural difference between human monoamine oxidases A dipartite to monopartite cavity conversion; (MAO A) and B (MAO B) is that MAO A has a monopartite substrate inhibitor specificity; monoamine oxidase B; cavity of 550 A˚3 volume and MAO B contains a dipartite cavity struc- mutations of gating residues; structure of ture with volumes of 290 A˚3 (entrance cavity) and 400 A˚3 (substrate methylene blue complex cavity). Ile199 and Tyr326 side chains separate these two cavities in MAO Correspondence B. To probe the function of these gating residues, Ile199Ala and Ile199Ala- D. E. Edmondson, Department of Tyr326Ala mutant forms of MAO B were investigated. Structural data on Biochemistry, Emory University, 1510 the Ile199Ala MAO B mutant show no alterations in active site geometries Clifton Road, Atlanta, GA 30322, USA compared with wild-type enzyme while the Ile199Ala-Tyr326Ala MAO B Fax: +1 404 727 2738 mutant exhibits alterations in residues 100–103 which are part of the loop Tel: +1 404 727 5972 gating the entrance to the active site. Both mutant enzymes exhibit catalytic E-mail: [email protected] properties with increased amine KM but unaltered kcat values. The altered *Present address KM values on mutation are attributed to the influence of the cavity struc- Department of Chemistry, Princeton ture in the binding and subsequent deprotonation of the amine substrate.
    [Show full text]
  • SYNTHESIS of 3-HETEROCYCLE PHENYL N-ALKYL CARBAMATES and THEIR ACTIVITY AS FAAH INHIBITORS Doctoral Dissertation
    TKK Dissertations 203 Espoo 2009 SYNTHESIS OF 3-HETEROCYCLE PHENYL N-ALKYL CARBAMATES AND THEIR ACTIVITY AS FAAH INHIBITORS Doctoral Dissertation Mikko Myllymäki Helsinki University of Technology Faculty of Chemistry and Materials Sciences Department of Chemistry TKK Dissertations 203 Espoo 2009 SYNTHESIS OF 3-HETEROCYCLE PHENYL N-ALKYL CARBAMATES AND THEIR ACTIVITY AS FAAH INHIBITORS Doctoral Dissertation Mikko Myllymäki Dissertation for the degree of Doctor of Philosophy to be presented with due permission of the Faculty of Chemistry and Materials Sciences for public examination and debate in Auditorium KE2 (Komppa Auditorium) at Helsinki University of Technology (Espoo, Finland) on the 19th of December, 2009, at 12 noon. Helsinki University of Technology Faculty of Chemistry and Materials Sciences Department of Chemistry Teknillinen korkeakoulu Kemian ja materiaalitieteiden tiedekunta Kemian laitos Distribution: Helsinki University of Technology Faculty of Chemistry and Materials Sciences Department of Chemistry P.O. Box 6100 (Kemistintie 1) FI - 02015 TKK FINLAND URL: http://chemistry.tkk.fi/ Tel. +358-9-470 22527 Fax +358-9-470 22538 E-mail: [email protected] © 2009 Mikko Myllymäki ISBN 978-952-248-240-2 ISBN 978-952-248-241-9 (PDF) ISSN 1795-2239 ISSN 1795-4584 (PDF) URL: http://lib.tkk.fi/Diss/2009/isbn9789522482419/ TKK-DISS-2686 Multiprint Oy Espoo 2009 3 AB HELSINKI UNIVERSITY OF TECHNOLOGY ABSTRACT OF DOCTORAL DISSERTATION P.O. BOX 1000, FI-02015 TKK http://www.tkk.fi Author Mikko Juhani Myllymäki Name of the dissertation
    [Show full text]
  • Parkinson Disease and Other Movement Disorders
    P1: Trim: 8.375in × 10.875in Top: 0.373in Gutter: 0.664in LWBK915-57 LWW-KodaKimble-educational September 17, 2011 2:31 Parkinson Disease and Other 57 Movement Disorders Michael E. Ernst and Mildred D. Gottwald CORE PRINCIPLES CHAPTER CASES PARKINSON DISEASE 1 Parkinson disease (PD) is a chronic, progressive movement disorder resulting from Case 57-1 (Questions 1, 2) loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia, postural disturbances, and tremor. 2 Treatment for PD is aimed at restoring dopamine supply through one, or a Case 57-1 combination, of the following methods: exogenous dopamine in the form of a (Questions 3–18), precursor, levodopa; direct stimulation of dopamine receptors via dopamine Case 57-2 (Questions 1, 2) agonists; and inhibition of metabolic pathways responsible for degradation of levodopa. 3 Therapy for PD is usually delayed until there is a significant effect on quality of life; Case 57-1 (Questions 4, 10) generally younger patients start with dopamine agonists, whereas older patients may start with levodopa. 4 Initial therapy with dopamine agonists is associated with a lower risk of developing Case 57-1 (Questions 4, motor complications than with levodopa, but all patients will eventually require 10–15) levodopa. 5 Advanced PD is characterized by motor fluctuations including a gradual decline in Case 57-1 (Questions on time, and the development of troubling dopaminergic-induced dyskinesias. 15–18), Case 57-2 Dopamine agonists, monoamine oxidase type B (MAO-B) inhibitors, and (Question 1), Case 57-3 catechol-O-methyltransferase (COMT) inhibitors can reduce motor fluctuations; (Questions 1, 2) amantadine can improve dyskinesias.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Metabolic Enzyme/Protease
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.
    [Show full text]
  • Laws, Rules, and Regulations
    LAWS, RULES, AND REGULATIONS August 2020 Asa Hutchinson, Governor John Clay Kirtley, Pharm.D. Executive Director Arkansas Department of Health Arkansas State Board of Pharmacy 322 South Main Street, Suite 600 Little Rock, AR 72201 Phone: 501.682.0190 Fax: 501.682.0195 [email protected] www.pharmacyboard.arkansas.gov 10/8/2020 Arkansas State Board of Pharmacy Members Lenora Newsome, P.D. President, Smackover Rebecca Mitchell, Pharm.D. Vice President/Secretary, Greenbrier Deborah Mack, P.D. Member, Bentonville Lynn Crouse, Pharm.D. Member, Lake Village Brian Jolly, Pharm.D. Member, Beebe Carol Rader, RN Public Member, Fort Smith Amy Fore, MHSA, FACMPE, FACHE Public Member, Fort Smith 10/8/2020 Board of Pharmacy Law Book - Acts Table of Contents Pharmacy Practice Act A 17-92-101 Definitions……………………………………………………… 1-4 17-92-102 Exemptions…………………………………………………….. 4-5 17-92-103 Pharmacy laws unaffected……………………………………... 5 17-92-104 Privilege tax unaffected……………………………………….. 5 17-92-105 Prohibited acts – Penalties……………………………………... 6 17-92-106 Injunctions……………………………………………………… 6 17-92-107 Prosecutions – Disposition of fines……………………………. 6 17-92-108 Fees…………………………………………………………….. 6-10 17-92-109 Prescriptions for optometrists………………………………….. 10 17-92-110 Prescriptive authority of advance practice nurses……………… 10 17-92-111 Construction of Acts 1997, No. 1204………………………….. 10 17-92-112 Prescriptions for physician assistants…………………………. 10 17-92-201 Members – Qualifications……………………………………… 11 17-92-202 Members – Oath……………………………………………… 11 17-92-203 Members – Compensation…………………………………….. 11 17-92-204 Organization and proceedings…………………………………. 12 17-92-205 Rules and regulations – Enforcement………………………….. 12-13 17-92-206 Issuance of bulletins – Annual Reports………………………... 14 17-92-207 Maintenance of office………………………………………….
    [Show full text]